The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Health authorities in Rio de Janeiro are reviewing samples from 288 donors after discovering that two HIV-positive people ...

Life challenges make this population very difficult to treat, but interventions that take their issues into account may ...